Arbutus’ LNP Licensee Alnylam Announces Positive Phase 3 Results for LNP-Enabled Patisiran Program
Go back to Arbutus’ LNP Licensee Alnylam Announces Positive Phase 3 Results for LNP-Enabled Patisiran Program| (NASDAQ: ABUS) | Delayed: 5.01 -0.06 (1.18%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $5.07 | 52 Week High | $5.88 | |||
| Open | $5.04 | 52 Week Low | $2.65 | |||
| Day High | $5.06 | P/E | N/A | |||
| Day Low | $4.98 | EPS | $0.00 | |||
| Volume | 6,458,530 | |||||
| Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) | Delayed: 239.56 -5.95 (2.42%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $245.51 | 52 Week High | $109.10 | |||
| Open | $246.41 | 52 Week Low | $31.38 | |||
| Day High | $246.49 | P/E | N/A | |||
| Day Low | $238.51 | EPS | $-1.45 | |||
| Volume | 2,756,179 | |||||
